# The Combination Therapy With Sorafenib in Therapeutic Strategy of Acute Myeloid Leukemia. Is It Promising? A Narrative Review

## TL;DR

This review explores whether combining sorafenib with other drugs improves outcomes in acute myeloid leukemia patients.

## Contribution

The paper provides a narrative review of combination therapies involving sorafenib for AML, highlighting varying remission and survival rates.

## Key findings

- Combining sorafenib with cytarabine and idarubicin achieved 99% complete remission.
- Sorafenib with quizartinib and midostaurin showed 80% overall survival.
- Chemotherapy combinations generally improved sorafenib's anticancer effectiveness.

## Abstract

Acute myeloid leukemia (AML) is the most common acute leukemia, which is associated with high morbidity and mortality, and its incidence rate is increasing. Despite tremendous advancements in AML treatment, managing the condition is still challenging. Receptor kinase inhibitors like sorafenib have recently raised concerns about monotherapy, and combination treatments are now being investigated as a potential therapeutic avenue. To classify medications taken in conjunction with sorafenib and analyze their combined effects, we reviewed the prior research findings.

A thorough literature search utilizing several databases, including PubMed, Google Scholar, Scopus, Embase, and Cochrane, yielded 78 relevant articles until October 2023. Search terms including AML, combination, and Sorafenib were utilized during the database search to find relevant papers.

Complete remission (CR) in the combination of sorafenib with “cytarabine and idarubicin”, “Vorinostat and Bortezomib, Clofarabine”, “Fludarabine and Busulfan”, “5‐azacytidine” and “Quizartinib, Midostaurin and Giltertinib” respectively “99% and 94%”, “27% and 3%”, 66.6%, “45%, 26%, 16%”, “71% and 52%”. Furthermore, the overall survival (OS) values for the combination of sorafenib with “Quizartinib, Midostaurin, and Giltertinib”, “cytarabine, daunorubicin” and “5‐azacitidine” were “80%” “62% 45%”, and 24%, respectively.

Accordingly, several studies suggest that sorafenib's anticancer effectiveness may be enhanced with chemotherapy drugs.